CLDX Key Stats
- Celldex Therapeutics to Present at Two Upcoming Investor Conferences GlobeNewswire May 22
- CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Termination of a Material Definit... May 20
- 5 Biotechnology Stocks to Buy Now Investor Place May 15
- Celldex Therapeutics' Management Presents at Credit Suisse Antibody Day Conferen... May 11
- 5 Biotechnology Stocks to Buy Now Investor Place May 8
- Celldex Therapeutics Announces Upcoming Presentation at the Credit Suisse 2013 A... May 6
- Predicting Biotech Stock Moves Using Top Consensus Picks By Legendary Fund Manag... May 5
- Investors Ride 5 Earnings Rollercoaster Rides May 4
- CELLDEX THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report May 3
- Celldex Therapeutics Earnings: Here’s Why Investors are Happy Now May 2
CLDX Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Celldex Therapeutics is up 191.1% over the last year vs S&P 500 Total Return up 27.96%, Array BioPharma up 67.29%, and Ariad Pharmaceuticals up 16.45%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for CLDX
Pro Report PDF for CLDX
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download CLDX Pro Report PDF
Pro Strategies Featuring CLDX
Did Celldex Therapeutics make it into our Pro Portfolio Strategies?